Entera Bio (ENTX) Gross Margin (2019 - 2024)

Entera Bio (ENTX) has reported Gross Margin for 5 consecutive years, with 15.79% the latest figure, recorded in Q2 2024.

• Quarterly Gross Margin changed N/A year-over-year to 15.79% in Q2 2024, while the trailing twelve-month figure through Mar 2025 was 4.04% (changed N/A YoY) and the FY2024 annual result came in at 4.97%, changed N/A from the prior year.
• Gross Margin slipped to 15.79% in Q2 2024 per ENTX's latest filing, from 42.86% in the prior quarter.
• Over the last five years, Gross Margin for ENTX reached as high as 53.57% in Q3 2021 and fell as low as 9.17% in Q2 2021.
• A 4-year average of 30.34% and a median of 25.0% in 2022 frame the typical range for Gross Margin.
• The largest YoY upside for Gross Margin was 2528 bps in 2022 against a maximum downside of 3291 bps in 2022.
• Year by year, Gross Margin stood at 40.38% in 2020, then sank by 56 bps to 17.58% in 2021, then surged by 144 bps to 42.86% in 2022, then slumped by 63 bps to 15.79% in 2024.
• According to Business Quant data, Gross Margin over the past three periods registered 15.79%, 42.86%, and 25.0% for Q2 2024, Q4 2022, and Q3 2022 respectively.